Zenas BioPharma develops immune system drugs for autoimmune diseases, led by the antibody candidate obexelimab. It last closed at $27.75 on Nov 17, down 0.64% on the day.
Only 1 firm rated ZBIO in the past 90 days, not enough for a consensus
Average 12-month target
$48.00
▲ 73.0% upside
Based on 1 analyst who set a price target on ZBIO in the past 90 days. The average target is $48.00, with a high of $48.00 and a low of $48.00, compared with the last close of $27.75.
Low $48.00Avg $48.00High $48.00
Blue marker: last close $27.75
Highest target$48.00
Average target$48.00
Lowest target$48.00
Latest rating changes
CitigroupMaintained
Sep 30Buy$48
Morgan StanleyMaintained
Aug 14Hold$32
WedbushReiterated
Aug 14Buy$45
Date
Firm
Action
Rating
Price target
Sep 30
Citigroup
Maintained
Buy
$48
Aug 14
Morgan Stanley
Maintained
Hold
$32
Aug 14
Wedbush
Reiterated
Buy
$45
Loading…
Technical Analysis
ZBIO · as of the Nov 17 close · updated after every close
Moving sideways
The stock is 1% below its 20 day and 2% below its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 49). The nearest support is the Pivot at $27.62, and the nearest resistance the 20 day average at $27.97.
Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$44.6052 week high+60.7%
$29.55100 day average+6.5%
$29.23Swing high (Oct 1)+5.3%
$28.3850 day average+2.3%
$28.25Pivot R1+1.8%
$27.9720 day average+0.8%
$27.75Last close
$27.62Pivot−0.5%
$27.12Pivot S1−2.3%
$26.68Swing low (Oct 26)−3.9%
$25.44200 day average−8.3%
$13.5052 week low−51.4%
Indicators
RSI (14)
48.74
Middle of its range
Neutral
MACD
-0.01
Above its signal line
Bullish
Stochastic
49.2
Middle of its range
Neutral
ADX (14)
12.7
No clear trend
Williams %R
-54.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-55.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−2.2%
Change over 10 sessions
Bearish
ATR (14)
$1.64
Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityLow, 13.3%/day
Key levels
$44.6052 week high+60.7%
$29.55100 day average+6.5%
$29.23Swing high (Oct 1)+5.3%
$28.3850 day average+2.3%
$28.25Pivot R1+1.8%
$27.9720 day average+0.8%
$27.75Last close
$27.62Pivot−0.5%
$27.12Pivot S1−2.3%
$26.68Swing low (Oct 26)−3.9%
$25.44200 day average−8.3%
$13.5052 week low−51.4%
Indicators
RSI (14)
51.05
Middle of its range
Neutral
MACD
0.68
Below its signal line
Bearish
Stochastic
38.6
Middle of its range
Neutral
ADX (14)
15.0
No clear trend
Williams %R
-64.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-67.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.8%
Change over 10 sessions
Bearish
ATR (14)
$3.70
Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for ZBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ZBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in ZBIO in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZBIO is in one of them and how their past ZBIO trades turned out.
Zenas BioPharma is a biopharmaceutical company based in Waltham, Massachusetts, that develops drugs targeting the immune system to treat autoimmune diseases. Its lead candidate, obexelimab, is an antibody designed to calm B cells, which play a role in conditions such as IgG4-related disease, relapsing multiple sclerosis and lupus. The company is also developing orelabrutinib, an oral drug for progressive forms of multiple sclerosis, along with several earlier stage candidates. It has no approved products and does not sell drugs today, so its intended customers are patients with autoimmune diseases and the doctors who treat them.